Paracetamol pilot study - Oral Vs Intravenous antidotes
- Conditions
- iver cell injury in paracetamol overdose
- Registration Number
- SLCTR/2017/036
- Lead Sponsor
- South Asian Clinical Toxicology Research Collaboration (SACTRC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Patients >16 years of age with acute paracetamol poisoning. i.e who present within 10 hours of ingestion and whose plasma paracetamol levels falls above Prescott normogram line.
1. Patients presenting more than 10 hours after poisoning.
2. Patients who have already received an antidote (possible in other hospitals prior to transfer).
3. Patients who have received charcoal (which would interfere with oral antidotes).
4. Patients under the age of 16.
5. Patients who are unable to give the amount of paracetamol ingested and the time of ingestion
6. Patients who are institutionalized for any mental health condition.
7. Patients with known cognitive impairment (e.g. dementia).
8. Patients with an unrelated life threatening illness (e.g. terminal cancer).
9. Patients who are known to be pregnant or breast feeding.
(This is simply a practical decision. There are no known risks these patients will be subjected to by being treated with these antidotes)
10. Patients who have had a paracetamol overdose in the previous 4 weeks or have taken a significant dose of any other toxic substance in addition to paracetamol.
11. Patients who are on warfarin.
12. Patients who have taken a staggered dose of paracetamol (over more than a 2-hour period).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rise of ALT to more than 50% of the baseline value within 24 hours. [On admission and at 8, 16, 24, and 36 hours post ingestion, and thereafter daily until discharge.]<br>
- Secondary Outcome Measures
Name Time Method